Sanofi-Aventis, P&G To Continue Actonel Collaboration
This article was originally published in The Pink Sheet Daily
The companies’ new agreement covers R&D and commercial efforts supporting the osteoporosis therapy, Sanofi-Aventis says. Procter & Gamble also will co-promote risedronate in “additional territories.”
You may also be interested in...
Change-in-control triggers discussion about future of Aventis partnerships. Sanofi notes that there is a defined timeline for negotiations, but the company is not making any details public.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products